NCT00272987 - ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

October 21, 2019

Conditions

Neoplasms, Breast

Interventions

DRUG

lapatinib

(GW572016) 1000 mg QD

DRUG

paclitaxel

80 mg/m2 IV weekly for three weeks

DRUG

trastuzumab

4 mg/kg loading dose and 2 mg/kg weekly IV

Trial Locations (16)

4000

Novartis Investigative Site, Liège

6700

Novartis Investigative Site, Arlon

23230

Novartis Investigative Site, Richmond

27103

Novartis Investigative Site, Winston-Salem

29406

Novartis Investigative Site, Charleston

30076

Novartis Investigative Site, Roswell

39202

Novartis Investigative Site, Jackson

43219

Novartis Investigative Site, Columbus

44718

Novartis Investigative Site, Canton

45042

Novartis Investigative Site, Middletown

48202

Novartis Investigative Site, Detroit

60435

Novartis Investigative Site, Joliet

77030

Novartis Investigative Site, Houston

79106

Novartis Investigative Site, Amarillo

08043

Novartis Investigative Site, Voorhees Township

77030-4009

Novartis Investigative Site, Houston